PEG-asparaginase

DRUG20 trials

Sponsors

Nordic Society for Pediatric Hematology and Oncology, Therapeutic Advances in Childhood Leukemia Consortium, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center, Emory University

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia (ALL)Acute Lymphoid LeukemiaB-cell Adult Acute Lymphoblastic Leukemia (ALL)Chemotherapeutic ToxicityGene AbnormalityLeukemiaLeukemia, Acute Lymphoblastic

Phase 1

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

TerminatedNCT00439296

Therapeutic Advances in Childhood Leukemia ConsortiumAcute Lymphoblastic Leukemia, Recurrent Pediatric ALL, Refractory Pediatric ALL +1

Start: 2006-05-22End: 2009-09-23Updated: 2021-03-17

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

CompletedNCT00440726

Therapeutic Advances in Childhood Leukemia ConsortiumAcute Lymphoblastic Leukemia

Start: 2006-08-04End: 2011-02-26Updated: 2020-02-19

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

WithdrawnNCT00957320

Emory UniversityAcute Lymphoblastic Leukemia

Start: 2009-06-30End: 2012-08-31Updated: 2013-12-03

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

TerminatedNCT01186328

Therapeutic Advances in Childhood Leukemia ConsortiumLeukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, T Cell, Lymphoblastic Leukemia, Acute +1

Start: 2010-08-24End: 2012-01-10Updated: 2024-02-01

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

CompletedNCT01324180

H. Lee Moffitt Cancer Center and Research InstituteAcute Lymphoblastic Leukemia

Start: 2011-07-18End: 2017-07-27Updated: 2017-08-07

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

CompletedNCT01523977

Dana-Farber Cancer InstituteAcute Lymphoblastic Leukemia

Start: 2011-11-30End: 2018-11-30Updated: 2024-07-18

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

CompletedNCT02303821

AmgenAcute Lymphoblastic Leukemia (ALL)

Start: 2015-02-16End: 2024-06-28Updated: 2025-06-04

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

CompletedNCT03349281

Julio Barredo, MDRefractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia

Start: 2019-03-25End: 2022-10-12Updated: 2022-10-20

Phase 2

ALL Adult Consortium Trial: Adult ALL Trial

CompletedNCT00476190

Dana-Farber Cancer InstituteAcute Lymphoblastic Leukemia

Start: 2007-04-30End: 2020-03-31Updated: 2025-06-12

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

CompletedNCT00866749

M.D. Anderson Cancer CenterLymphoblastic Leukemia, Lymphoblastic Lymphoma

Start: 2006-09-12End: 2018-07-26Updated: 2019-09-10

Treatment of Older Adults With Acute Lymphoblastic Leukemia

CompletedNCT00973752

Massachusetts General HospitalAcute Lymphoblastic Leukemia

Start: 2009-08-31End: 2016-04-30Updated: 2017-03-30

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

CompletedNCT01451515

St. Jude Children's Research HospitalLymphoblastic Lymphoma

Start: 2012-05-25End: 2022-05-31Updated: 2022-06-28

Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

CompletedNCT01769209

Stanford UniversityB-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL), Recurrent Adult Acute Lymphoblastic Leukemia (ALL) +1

Start: 2013-03-31End: 2017-07-04Updated: 2018-11-14

A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Active, not recruitingNCT01920737

Memorial Sloan Kettering Cancer CenterLeukemia

Start: 2013-08-07End: 2026-08-31Updated: 2025-09-16

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

TerminatedNCT02518750

St. Jude Children's Research HospitalAcute Lymphoblastic Leukemia, Leukemia, B-Cell, Leukemia, T-Cell +1

Start: 2016-11-23End: 2018-03-11Updated: 2019-04-03

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

CompletedNCT03384654

Janssen Research & Development, LLCPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Start: 2018-05-14End: 2022-09-27Updated: 2025-05-25

Phase 3

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

CompletedNCT02393859

AmgenLeukemia, Acute Lymphoblastic

Start: 2015-11-10End: 2022-11-21Updated: 2024-05-29

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

CompletedNCT02881086

Goethe UniversityAcute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

Start: 2016-08-31End: 2024-12-31Updated: 2025-12-16

Phase 4

Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

Nordic Society for Pediatric Hematology and OncologyAcute Lymphoblastic Leukemia

Start: 2005-06-30End: 2013-12-31Target: 85Updated: 2009-09-30

Unknown Phase

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

RecruitingNCT05959720

Instituto do Cancer do Estado de São PauloAcute Lymphoid Leukemia, Chemotherapeutic Toxicity, Gene Abnormality +1

Start: 2023-09-05End: 2030-06-30Target: 180Updated: 2025-05-07

Related Papers

Cost-utility analysis of blinatumomab in pediatric patients with acute lymphoblastic leukemia in Iran.

2025-10-15

<i>Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013</i>

Blood2024-11-053 citations

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Blood2024-11-053 citations

Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico.

2024-08-224 citations

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Blood2024-08-1937 citations

<i>CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy</i>

Blood2023-11-02

P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13

HemaSphere2023-08-015 citations

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial

Blood Advances2023-06-0526 citations

Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Blood2022-11-154 citations

Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.

Journal of Clinical Oncology2022-06-0132 citations

P359: IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

HemaSphere2022-06-01

Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia

Pediatric Blood & Cancer2022-04-2823 citations

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Blood2021-11-0524 citations

Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Blood2021-11-051 citations

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

Blood2021-11-051 citations

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Blood2021-11-051 citations

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

JAMA2021-03-02310 citations

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia

Haematologica2020-10-1342 citations

Immunotherapies for Pediatric B-Cell Acute Lymphoblastic Leukemia Patients

Oncology Times2019-04-25

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Blood2018-11-294 citations

6 more papers not shown